PLUS1
Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 7.62 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Dermira Inc | DERM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.09 | 1.2% | 7.62 | 7.72 | 7.431 | 7.61 | 7.53 | 19:59:41 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 7.01 | 9.00 | 1.99 | 22.11% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,774 | 777,463 | $ 7.61 | $ 5,918,051 | 1,662,738 | 5.25 - 15.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:17:12 | 1 | $ 7.61 | USD |
Dermira Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 415.45M | 54.52M | $ -221.54M | -5.27 | - | 54.19M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 20.00 | 0.60% |
Dermira News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/14/2019 | 16:05 | Business Wire | Dermira Presents New Scientific Research Findings from the.. |
| 11/13/2019 | 17:47 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/13/2019 | 17:47 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/13/2019 | 17:35 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 11/13/2019 | 17:35 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 11/13/2019 | 16:22 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/13/2019 | 16:05 | Business Wire | Dermira Elects Halley E. Gilbert to its Board of Directors |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DERM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.51 | 9.39 | 7.25 | 8.14 | 2,513,223 | -0.89 | -10.46% |
| 1 Month | 5.80 | 9.39 | 5.80 | 7.37 | 2,103,018 | 1.82 | 31.38% |
| 3 Months | 8.92 | 9.48 | 5.25 | 7.25 | 1,160,050 | -1.30 | -14.57% |
| 6 Months | 10.33 | 10.82 | 5.25 | 7.99 | 872,882 | -2.71 | -26.23% |
| 1 Year | 9.74 | 15.48 | 5.25 | 9.91 | 1,140,146 | -2.12 | -21.77% |
| 3 Years | 35.20 | 38.75 | 5.25 | 13.96 | 815,301 | -27.58 | -78.35% |
| 5 Years | 16.00 | 38.75 | 5.25 | 15.45 | 551,109 | -8.38 | -52.38% |
Dermira Description
| Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. |
